Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 4Recruiting 2Completed 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 4Other neoplasm 2Myeloid 2Head & Neck 2Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 173Head and Neck Neoplasms 140Thyroid Neoplasms 59Carcinoma, Non-Small-Cell Lung 58Oropharyngeal Neoplasms 48Melanoma 47Nasopharyngeal Carcinoma 45Colorectal Neoplasms 33Mouth Neoplasms 30Carcinoma, Renal Cell 29Breast Neoplasms 27Uterine Cervical Neoplasms 26Neoplasms 26Ovarian Neoplasms 25Stomach Neoplasms 24Carcinoma, Squamous Cell 23Lung Neoplasms 22Esophageal Neoplasms 22Triple Negative Breast Neoplasms 20Neoplasm Metastasis 20Endometrial Neoplasms 20Salivary Gland Neoplasms 19Thyroid Cancer, Papillary 16Pancreatic Neoplasms 16Sarcoma 15Laryngeal Neoplasms 15Urinary Bladder Neoplasms 13Prostatic Neoplasms 13Colonic Neoplasms 13Carcinoma, Transitional Cell 13

Interventions

Cisplatin 2pembrolizumab 1Taxes 1Radiotherapy, Intensity-Modulated 1Pemetrexed 1Paclitaxel 1Nimorazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms by Histologic Type × Head & Neck × Clear all
NCT04124198 2025-12-31

QoLATI

Rigshospitalet, Denmark

Phase NA Active not recruiting
138 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡